-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. With Losses of $100,000 to Contact the Firm
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. With Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - February 8, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd" or "the Company") (NASDAQ: IVVD) (NASDAQ: ADGI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between November 29, 2021 and December 14, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before April 3, 2023.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at , or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Invivyd's studies and analyses that it claimed to demonstrate ADG20's effectiveness against the Omicron variant were unreliable and ineffective. The Company's claims about the effectiveness of ADG20 were not supported by facts. In fact, ADG20 was 300 times less effective against Omicron as against prior variants of COVID-19. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Invivyd, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
Office: 310-301-3335
info@schallfirm.com
SOURCE:
The Schall Law Firm
To view the source version of this press release, please visit
Los Angeles, California--(Newsfile Corp. - February 8, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd" or "the Company") (NASDAQ: IVVD) (NASDAQ: ADGI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
加利福尼亞州洛杉磯-(Newsfile Corp.-2023年2月8日)-全國性股東權利訴訟公司Schall律師事務所提醒投資者，一起針對因維德公司(Invivyd，Inc.)(“Invivyd”或“本公司”)(納斯達克：IVVD)(納斯達克：ADGI)的集體訴訟，指控其違反1934年證券交易法第10(B)和20(A)節以及美國證券交易委員會頒佈的規則10b-5。
Investors who purchased the Company's securities between November 29, 2021 and December 14, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before April 3, 2023.
鼓勵在2021年11月29日至2021年12月14日期間(首尾兩日包括在內)購買本公司證券的投資者在2023年4月3日之前與本公司聯繫。
If you are a shareholder who suffered a loss, click here to participate.
如果您是蒙受損失的股東，請單擊此處參與。
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at , or by email at bschall@schallfirm.com.
我們還鼓勵您聯繫Schall律師事務所的Brian Schall，2049世紀公園東區，加州洛杉磯2460Suit2460，郵編：90067，電話：310-3013335，討論您的免費權利。您也可以通過公司的網站或電子郵件bschall@schallffer.com聯繫我們。
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
在這種情況下，該課程尚未獲得認證，在獲得認證之前，您不會由律師代表。如果你選擇不採取行動，你可以保持缺席班級成員的身分。
According to the Complaint, the Company made false and misleading statements to the market. Invivyd's studies and analyses that it claimed to demonstrate ADG20's effectiveness against the Omicron variant were unreliable and ineffective. The Company's claims about the effectiveness of ADG20 were not supported by facts. In fact, ADG20 was 300 times less effective against Omicron as against prior variants of COVID-19. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Invivyd, investors suffered damages.
根據起訴書，該公司向市場做出了虛假和誤導性的陳述。Invivyd聲稱證明ADG20對奧密克戎變體有效的研究和分析是不可靠和無效的。該公司關於ADG20有效性的說法沒有事實支持。事實上，與之前的奧密克戎變種相比，ADG20對新冠肺炎的效果要低300倍。基於這些事實，公司的公開聲明在整個課程期間都是虛假的，具有重大誤導性。當市場得知Invivyd的真相時，投資者蒙受了損失。
Join the case to recover your losses.
加入這個案子，挽回你的損失。
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Schall律師事務所代表世界各地的投資者，專門處理證券集體訴訟和股東權利訴訟。
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
根據適用的法律和道德規則，本新聞稿在某些司法管轄區可能被視為律師廣告。
CONTACT:
聯繫方式：
The Schall Law Firm
Brian Schall, Esq.,
Office: 310-301-3335
info@schallfirm.com
沙爾律師事務所
布萊恩·舒爾，Esq.
辦公室：310-301-3335
郵箱：Info@schallFirm.com
SOURCE:
資料來源：
The Schall Law Firm
沙爾律師事務所
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧